Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: Biomarin | Vintage Vibes

A $4.8 Billion Reason to Buy BioMarin Stock Today

BioMarin stock soars as the biotech firm announces a $4.8 billion acquisition of Amicus Therapeutics. The transaction could push BMRN shares even higher in 2026.

Barchart

Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings

Biomarin Pharmaceutical Inc (NASDAQ:BMRN) reported weaker-than-expected earnings for the third quarter on Monday.

Benzinga

PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment

On Saturday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released new Phase 3 PEGASUS study results on Saturday.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

On Tuesday, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) reported second-quarter adjusted earnings of $1.44, up 50% year over year, beating the consensus of 85 cents and sales of $825.41 million, up 16%, beating the consensus of $760.39 million.

Benzinga

‘Half the place would be blown to bits’: the Irish villages under threat from Trump’s tariffs

Cork’s pharmaceutical industry, vital to the local economy, is at risk as US trade policies threaten small towns reliant on the sector

The Guardian - UK

Can BioMarin Stock Live Up to Wall Street’s High Expectations?

BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon?

MarketBeat

2 'Strong Buy'-Rated Stocks That Could Rally 39% to 48% in 2025

Both of these growth stocks are positioned for long-term success.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Innovating in Biotech This Stock Targets Unmet Medical Needs for Big Profit

Most biotechnology companies have a broad mandate to perform research and development that addresses the largest market possible. It makes logical sense, the largest market should be the most profitable. But Biomarin stands this model on its head, providing drug treatments for highly specialized, mostly small markets that are underserved,…

StockNews.com

Gene therapy for severe hemophilia is approved by FDA

U.S. health regulators have approved a gene therapy for the most common form of hemophilia

The Independent UK

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients. BioMarin shares traded as high as 2.28 percent, in a range of $91.39 to $93.68…

Benzinga

BioMarin Achieves Record Q1 Sales Driven By Recently Approved Achondroplasia Therapy

BioMarin Pharmaceutical Inc's (NASDAQ:BMRN) Q1 sales reached $519 million, up 7% Y/Y, beating the consensus of $507.52 million. BioMarin said that the increase was achieved "despite continued erosion of the U.S. Kuvan market." Kuvan is indicated for phenylketonuria. Kuvan still brought in $59.3 million but down from $70.8 million a year ago.…

Benzinga

BioMarin Clocks Flat Q4 Sales Despite Erosion oF US Kuvan Market

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) reported a 1% Y/Y decrease in Q4 revenue to $449.8 million, beating the consensus estimate of $442.39 million. The decline was attributable to lower sales from Kuvan and Naglazyme, cushioned by higher revenues from Aldurazyme, Vimizim, and Palynziq. Kuvan sales decreased 23% to $ 68.5 million, primarily due…

Benzinga

FDA Asks For More Data To Resolve BioMarin's Gene Therapy Clinical Hold

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) said that the

Benzinga

BioMarin Sells Priority Review Voucher For $110M

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has agreed to sell the Rare Pediatric Disease Priority Review Voucher (PRV)

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

US Food and Drug Administration

BioMarin Pharmaceutical Inc

23 stories

Apellis Pharmaceuticals

Biomarin Pharmaceutical

12 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.